Table 1.

Outcome of therapy of chronic osteomyelitis due toS. aureusa

Antimicrobial therapyNo. of animalsMedian log10 CFU/g of boneRange (25th–75th percentile)
None165.094.59–5.49
Linezolid b.i.d.165.324.54–5.75
Linezolid t.i.d.134.903.03–5.70
Cefazolin153.782.81–4.36
  • a Linezolid dosed b.i.d, was not significantly different than no treatment; linezolid dosed t.i.d. was not significantly different than no treatment or cefazolin. Cefazolin was more active (P = 0.001) than no treatment or linezolid dosed b.i.d.